Two-year-outcomes analysis of Crohn’s disease treated with rifabutin and macrolide antibiotics

G. P. H. Gui, P. R. S. Thomas†, M. L. V. Tizard, J. Lake, J. D. Sanderson‡ and J. Hermon-Taylor*

University Department of Surgery, St George’s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK

Fifty-two patients with severe Crohn’s disease were enrolled in this study. Six (11.5%) were intolerant of the medication and had to be excluded. The remaining 46 patients were treated with rifabutin in combination with a macrolide antibiotic (clarithromycin or azithromycin). Patients were treated for a mean of 18.7 (range 6–35) months and followed up for 25.1 (range 7–41) months. Of the 19 patients who were steroid dependent at the start of this study, only two continued to require steroids when treatment was established. A reduction in the Harvey–Bradshaw Crohn’s disease activity index occurred after 6 months’ treatment \( (P = 0.004, \text{paired Wilcoxon test}) \) and was maintained at 24 months \( (P < 0.001) \). An improvement in inflammatory parameters was observed as measured by a reduction in erythrocyte sedimentation rate \( (P = 0.009) \) and C-reactive protein \( (P = 0.03) \) at 18 months compared with pretreatment levels, and an increase in serum albumin at 12 months \( (P = 0.04) \). When subsets of the study population were analysed, patients with pan-intestinal disease achieved better remission at 2 years than those with less extensive involvement \( (P = 0.04, \text{Mann–Whitney U-test}) \). No difference in treatment response by age, disease duration, the presence of granulomas on histology, or the occurrence of drug-induced side-effects, was observed. These data suggest that treatment with rifabutin and clarithromycin or azithromycin may result in a substantial clinical improvement in Crohn’s disease and justify the conduct of a randomized controlled trial.

Introduction

While the cause of Crohn’s disease remains controversial, evidence for the involvement of Mycobacterium paratuberculosis has been accumulating from both long-term culture\(^1–^8\) and polymerase chain reaction (PCR) tests on diseased tissue.\(^9–^15\) M. paratuberculosis is a specific chronic enteric pathogen capable of affecting many animal species including primates.\(^16,17\) Recent evidence suggests that this organism may be conveyed to humans in pasteurized cows’ milk.\(^18\) Although case reports and a small open study using antitubercular drugs to treat Crohn’s disease have shown promising results,\(^19,20\) the efficacy of this approach has never been confirmed in randomized controlled trials.\(^21–^23\) M. paratuberculosis, like other Mycobacterium avium, is generally resistant to standard antitubercular drugs, and in-vivo infections are known to be difficult to eradicate.\(^24\) Rifabutin, clarithromycin and azithromycin are a new generation of antibiotics which may have enhanced activity against M. paratuberculosis.\(^25–^28\) This paper presents an outcomes analysis of the efficacy of these drugs used in combination for the treatment of Crohn’s disease.

Patients and methods

Fifty-two patients with Crohn’s disease, most of whom had persistent and severe symptoms refractory to conventional treatment, were studied. Six patients had to be excluded, one due to acute uveitis and five due to intolerance of the medication comprising general malaise, lethargy, arthralgia, nausea and vomiting. The evaluable study population therefore consisted of 46 patients. The...
details of patients at entry into the study are given in the Table. Forty-two (91.3%) patients were selected for rifabutin and macrolide antibiotic therapy (RMAT) as they were no longer responsive to standard medical therapy. Seven (15.2%) patients had been on steroids alone, 19 (41.3%) patients had taken steroids and sulphasalazine or mesalazine, four patients (8.7%) steroids and azathioprine, seven (15.2%) patients steroids, azathioprine and sulphasalazine or mesalazine, and five (10.9%) patients sulphasalazine or mesalazine alone. Nineteen patients were steroid dependent at the start of RMAT. Four (8.7%) new patients were started directly on RMAT because of extensive active Crohn’s disease. Previous surgery had been undertaken before commencing RMAT in 26 (46.5%) of the patients. The duration of disease, and extensive previous drug treatment and surgery, reflect the usual clinical pattern seen in patients referred to tertiary centres specializing in the management of inflammatory bowel disease.

Patients were included in the study if they had an established diagnosis of active Crohn’s disease on clinical, radiological (barium studies and/or technetium-99 white-cell scan) and histopathological grounds. Granulomas were identified in the diseased tissue sections of 60% of patients. The RMAT regimen consisted of rifabutin 300 mg in the morning and 150 mg at night (Mycobutin, Pharmacia Ltd, Milton Keynes, U K) and either clarithromycin 250 mg twice daily (Klaricid, Abbott Laboratories Ltd, Queenborough, U K) or azithromycin 500 mg in a single daily dose for 4 consecutive days each week (Zithromax, Pfizer Ltd, Sandwich, U K). Forty-three patients were treated with a combination of rifabutin and clarithromycin of whom ten had also received a quinolone (either ciprofloxacin 500 mg twice daily (Bayer plc, Newbury, U K) or ofloxacin 200 mg twice daily (Roussel Laboratories Ltd, U xbridge, U K)). Five patients received clofazamine 100 mg once daily (Geigy Pharmaceuticals, Horsham, U K) in addition to rifabutin and clarithromycin. Three patients were treated with rifabutin and azithromycin alone. Patients received RMAT for a mean duration of 18.7 months (median 18 months, range 6–35 months).

The mean follow-up time after commencing RMAT was 25.1 months (median 28 months, range 8–41 months). Data were extracted from the hospital records with the following outcome measures as end points: Harvey–Bradshaw activity index,29 haemoglobin, white blood cell and platelet counts; erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and albumin; body mass index; liver biochemistry profile; steroid dependency and the need for surgery during or after commencing RMAT. Each of these parameters was analysed at 6 month inter-

<table>
<thead>
<tr>
<th>Table. Details of patients at entry into the study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
</tr>
<tr>
<td>male</td>
</tr>
<tr>
<td>female</td>
</tr>
<tr>
<td><strong>Site</strong></td>
</tr>
<tr>
<td>small bowel</td>
</tr>
<tr>
<td>large bowel</td>
</tr>
<tr>
<td>small and large bowel</td>
</tr>
<tr>
<td>perianal disease</td>
</tr>
<tr>
<td>extra-gastrointestinal</td>
</tr>
<tr>
<td>arthralgia</td>
</tr>
<tr>
<td>eyes</td>
</tr>
<tr>
<td>skin</td>
</tr>
<tr>
<td><strong>Mean</strong></td>
</tr>
<tr>
<td>Age at start of RMAT (years)</td>
</tr>
<tr>
<td>Duration from diagnoses (months)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
</tr>
<tr>
<td>Haemoglobin (g/dL)</td>
</tr>
<tr>
<td>White cell count (× 10⁹/L)</td>
</tr>
<tr>
<td>Platelet count (× 10⁹/L)</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate (mm/h)</td>
</tr>
<tr>
<td>C-reactive protein (mg/L)</td>
</tr>
<tr>
<td>Albumin (g/L)</td>
</tr>
<tr>
<td>Harvey–Bradshaw activity index</td>
</tr>
</tbody>
</table>
vals for up to 2 years and compared with pre-treatment values using the paired Wilcoxon test. The number of patients within each time frame after starting RMAT was: 6 months, \( n = 46 \); 12 months, \( n = 45 \); 18 months, \( n = 41 \); and 24 months, \( n = 29 \). White cell scans were performed after completion of RMAT in 11 patients in whom pretreatment images were also available for comparison.

The Cox proportional hazard survival analysis model was used to evaluate the maintenance of remission during and after RMAT. Subset analysis using the Mann–Whitney \( U \)-test was performed at 12 and 24 months to determine if there was a measurable difference in the Harvey–Bradshaw activity index in response to RMAT for each of the parameters.

**Results**

**Harvey–Bradshaw Crohn’s disease activity index**

Disease activity measured by the Harvey–Bradshaw index was significantly reduced within 6 months of commencing RMAT and was maintained for 24 months (Figure 1). Clinical remission (Harvey–Bradshaw activity index < 5) was induced in 43 (93.5%) patients. Life table estimates of remission maintenance during and after treatment with RMAT derived by Cox proportional hazard survival analysis, are shown in Figure 2. Of patients in whom a clinical remission was induced, the cumulative probability of remaining in remission after 24 months of RMAT was 68.7%.

**Inflammatory markers**

The mean (median) ESR progressively fell from 18.5 (24) (range 5–118) mm/h pretreatment with RMAT, to 11.8 (11) (range 1–26) mm/h at 18 months (\( P = 0.009 \), paired Wilcoxon test). Correspondingly, the CRP fell from a mean (median) of 23.5 (8.3) (range 4.0–109.0) mg/L pretreatment, to 17.3 (4.0) (range 1.4–50.3) mg/L at 18 months (\( P = 0.03 \)). A significant increase in serum albumin compared with the pretreatment value (Table) was observed at 12 and 18 months after commencement of RMAT, median value 40.0 g/L (\( P = 0.05 \)) and 40.5 g/L (\( P = 0.04 \)), respectively.

**Haematological parameters**

After 18 months of treatment with RMAT, there was a significant increase in the median haemoglobin concentration (16.1 g/dL, \( P = 0.01 \)) and a significant decrease in the platelet count (281.5 × 10^9/L, \( P = 0.01 \)) compared with the pretreatment levels listed in the Table (paired Wilcoxon test). RMAT did not influence the median white blood cell count of the study population throughout the course of treatment.

**Nutritional status**

RMAT had no overall effect over the period of study on either the body mass index or body weight in this cohort of patients.
Liver biochemistry

The mean (median) concentration of the serum liver enzymes before R M A T were: alkaline phosphatase, 85.8 (68.5) (range 33–286) mmol/L; alanine transaminase, 17.3 (13.5) (range 4–54) mmol/L; bilirubin, 8.5 (6.0) (range 2–65) μmol/L. R M A T had no significant effect on serum levels of alkaline phosphatase, alanine transaminase or bilirubin over the course of treatment.

A later drug therapy required during R M A T

At the time of commencing R M A T, 19 patients were steroid dependent, requiring a median cumulative dose of oral prednisolone over the preceding 6 months of 1575 g (range 81–5460 g). Steroid requirements over the period of study were significantly reduced when assessed by the paired Wilcoxon test: 6 months, median 445 g (range 0–3640 g), P < 0.001; 12 months, median 0 (range 0–1820 g), P < 0.001; 18 months, median 0 (range 0–5740 g), P = 0.001; 24 months, median 0 (range 0–4550 g), P = 0.007. Of the 19 patients who were on oral prednisolone at the time of starting R M A T, 12 were on steroids at 6 months and four at 12 months; only two patients remained steroid dependent at 2 years.

Thirty-one patients had been treated with a 5-amino salicylic acid derivative, and 11 patients had received azathioprine, at some stage before starting R M A T. Of these, only three patients continued to require either sulphasalazine or mesalazine, and three patients required azathioprine during or at the end of treatment with R M A T.

Surgery during or after R M A T

A total of 15 (32.6%) patients required an operation during the course of R M A T. Indications for surgery were stricture formation in a segment of irreversibly damaged bowel in ten (66.7%) patients, fistula or abscess formation in three (20%) patients and active disease not controlled by medication in two (13.3%) patients. There were five (33.3%) ileal resections and/or stricturoplasties, seven (46.7%) ileocaecal resections, two (13.3%) large bowel resections, and one (6.7%) laparotomy with biopsy only. To exclude the possibility that surgery itself might have been responsible for the improvement in the Harvey-Bradshaw activity index attributed to R M A T (Figure 1), the disease activity analysis was repeated excluding the patients who had operations on treatment. The P-values by the paired Wilcoxon test compared with the pretreatment activity indices were P = 0.03 at 6 months (n = 32), P = 0.002 at 12 months (n = 28), P = 0.01 at 18 months (n = 23) and P = 0.02 at 24 months (n = 16). Although the scale of the clinical response appeared to be reduced by exclusion of the patients who underwent surgery on treatment, the overall significant improvement in disease activity was maintained up to 24 months.

Subset analysis

Patients who had both small and large bowel disease appeared to do better than patients who had small bowel disease alone at 24 months, using median scores of the Harvey-Bradshaw activity index (P = 0.04, Mann-Whitney U-test). Subsets analysed by age (greater or less than 21 years), duration of disease (greater or less than 24 months from diagnosis), body mass index (greater or less than 20 kg/m²), the presence or absence of granulomas on histology, extra-gastrointestinal manifestations, the necessity for surgery during the study period, gender and smoking, revealed no significant difference in improvement as a result of R M A T at 12 and 24 months compared with pretreatment values. Likewise, there was no difference in clinical response to R M A T if patients were categorized according to whether surgery was required before treatment.

Post-treatment imaging investigations

Eleven patients had white cell scans on completion of R M A T that could be compared with pretreatment scans. Six scans were unchanged, one showed continued activity but improvement after R M A T, and four showed complete remission with no evidence of residual active disease. An example of a white cell scan showing a major treatment response is illustrated in Figure 3.

Side-effects and non-compliance

The commonest, yet non-distressing, side-effect was pseudojanudice, which caused yellow skin discoloration in 41 (89.1%) patients. Significant arthralgia was experienced by 23 (50%) patients. Four (8.7%) patients developed a maculopapular skin eruption, two (4.3%) suffered from dry eyes and there was a transient elevation of serum liver enzymes in one (2.2%) patient. Reversible rifabutin-induced acute uveitis occurred in four (8.7%) of the 46 patients studied. Two (4.3%) patients developed a transient neutropenia within a month of starting R M A T, with a white cell count of less than 3.0 × 10^9/L. While symptoms of general malaise usually resolved within the first 3 months of treatment, 18 (39.1%) patients continued to experience arthralgia beyond this time.

Discussion

Previous randomized controlled trials to evaluate the use of a variety of antimycobacterial chemotherapeutic agents in Crohn’s disease have not shown significant benefit in treatment compared with placebo controlled groups.21-23 Some of these trials may be criticized on the basis of single-agent therapy or the selection of inappropriate drugs, particularly for use against spheroplast forms of M.
paratuberculosis in vivo. Combinations of quadruple therapy have been shown to be effective in the relief of symptoms and maintenance of remission in patients with active or steroid-dependent Crohn's disease. None of these trials evaluated a combination of rifabutin and the newer macrolide antibiotics, which are predicted to have greater activity against the specific chronic enteric pathogen M. paratuberculosis in vivo. Recent studies using this treatment regime in disseminated M. avium complex infections in patients with acquired immune deficiency syndrome have shown promising results.

Rifabutin is a synthetic rifamycin with greater bactericidal potential against M. paratuberculosis than rifampicin. In addition to the known effect on DNA-dependent RNA polymerase in bacteria, rifabutin has been shown to inhibit reverse transcriptase in HIV-1. Clarithromycin is also effective against M. paratuberculosis, and early reports using single-agent therapy demonstrated clinical efficacy in the treatment of active Crohn's disease in a randomized double blind crossover trial. The combination of rifabutin and clarithromycin has been shown to be additive against M. avium in vitro. The accumulation of the newer macrolide antibiotics including clarithromycin and azithromycin within human polymorphonuclear leucocytes and macrophages may account for the enhanced efficacy against M. avium complex infections. The effects of the macrolide antibiotics alone or in combination may be potentiated by granulocyte-macrophage colony-stimulating factor or tumour necrosis factor.

The accurate assessment of activity in Crohn's disease is notoriously difficult. The Harvey-Bradshaw index represents a simplified yet reliable means of achieving this. Crohn's disease activity assessed by the Harvey-Bradshaw index was significantly reduced 6 months after commencement of RMAT, and maintained at 24 months. During this period, there was an objective improvement in the inflammatory markers (ESR, CRP and albumin), haematological parameters (haemoglobin and platelet count) and steroid requirements. Body weight is not a reliable marker of the overall presence or absence of clinical response in patients with Crohn's disease. Patients overweight due to steroid dependency at the start of RMAT, lost weight when they responded to RMAT enabling steroids to be withdrawn, whereas thin malnourished patients demonstrated a substantial weight gain in response to RMAT. To exclude the possibility that improvements in the Harvey-Bradshaw activity index occurred because of surgical intervention during the RMAT treatment period, disease activity was reassessed.

Figure 3. White cell scan of a 22 year old female patient (a) before combined treatment with rifabutin and clarithromycin showing (arrow) active inflammation in the diseased bowel, and (b) 22 months after treatment showing complete abolition of abnormal technetium-99 uptake. At this time the patient was, and remains, symptom free.
with the patients who had operations excluded. Significant clinical improvement was still observed from 6 months after commencing R M A T and maintained until 24 months. Remission on R M A T was maintained in approximately two-thirds of the patients studied after 2 years.

Subset analysis of the study population did not identify any groups that were more likely to do well on R M A T with the exception of patients with both small and large bowel involvement, who achieved a better clinical response than patients with small bowel disease alone. This may be because clinical improvement in patients with extensive disease might have been easier to detect. Symptoms from Crohn’s disease in humans arise from acute and chronic inflammation, superimposed on structural abnormalities such as strictures, fistulas and irreversibly damaged. Variation in the exact cause of each patient’s symptoms, compounded by uncertainty in the interpretation of a finite therapeutic response on clinical, radiological or endoscopic grounds, might account for inconclusive results from small trials on the efficacy of R M A T in the treatment of Crohn’s disease. Difficulty in culturing M. paratuberculosis and establishing growth in vitro precludes the establishment of strict culture-based microbiological criterion for disease eradication and cure. Future trials in Crohn’s disease should monitor M. paratuberculosis in sequential endoscopic biopsies using hybridization capture of target DNA and IS900 PCR, together with the detection of IS900 RNA.

In conclusion, these data suggest that treatment with rifabutin in conjunction with a macrolide antibiotic is a safe combination which may induce and maintain remission as well as abolish steroid dependency in refractory Crohn’s disease. A proportion of patients with extensive Crohn’s disease resistant to standard medical therapy respond to R M A T, further evaluation of this treatment as an additional therapeutic option is of great importance. These results justify a randomized, controlled trial to assess the efficacy of this therapeutic approach taking into account the standards for approval of new drugs for inflammatory bowel diseases.

Acknowledgements

This research was supported by grants from Action Research and The Ileostomy Association, to whom we express our gratitude.

References

Rifabutin and macrolide therapy of Crohn’s disease


*Received 10 September 1996; returned 21 October 1996; revised 7 November 1996; accepted 12 December 1996*